Sharemaestro company-news research for Naturgy Energy Group, S.A. (NTGY), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
MCE
Spain
Measured evidence
Company news sentiment
NTGY news sentiment
Naturgy Energy Group, S.A.
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone61Neutral is 50
Constructive news tone
72/100 evidence confidence
100% direct company focus
7 current stories across 1 publishers
Current company news
Balanced read
Constructive news tone is drawn from 7 fresh independent stories, including 7 company-specific items across 1 publishers.
Latest source headline Nextensa delivers strong half-year results, supported by several successful transactions finance.yahoo.com · 12 Aug 2026 15:55What supports the read
7 current stories are mapped specifically to NTGY.
Cross-story agreement is 84/100, indicating a comparatively coherent tape.
What tempers the read
Only 1 publisher currently contribute to the measured read.
61/100
Weighted toneConstructive news tone
72/100
Evidence confidencesolid confidence
100%/100
Company focus7 direct stories
84/100
Evidence agreement16/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth76
6.05 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness79
recency-weighted evidenceAgreement84
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
News tone and price action are not far from neutral.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment confirms active trend
News subjects
What is shaping the score
Earnings686 stories · 86%
Regulatory and legal591 stories · 14%
Source mix
Where the evidence comes from
finance.yahoo.com667 stories · 100%
Recurring subjects
Subjects appearing most often
Earnings5Revenue Growth2Guidance2Growth Rate2Fda Approval2Biotech2Balance Sheet2Transactions1Supply Chain1Revenue1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#138Tone
finance.yahoo.comDirect company coverage
Nextensa delivers strong half-year results, supported by several successful transactions
Nextensa NV PRESS RELEASE Regulated information Brussels, 12 August 2026, 5:55PM HIGHLIGHTS Nextensadeliversstronghalf-yearresults,supportedbyseveralsuccessful transactions Nextensa achieved strong results in the first half of 2026. The period was marked by several successful transactions, including the sale of Gewerbepark Stadlau in Vienna, the forward sale of The Rock and the sale of B&B Hotels in Cloche d'Or. The granting of the planning and environmental permits for Lake Side in Brussels and the reservation by Vicinity of a substantial residential portion of Bel Towers further underline th
Balance SheetDevelopmentDividendsFinancialsReal EstateTransactions
- Published
- 12 Aug 2026 15:55
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#259Tone
finance.yahoo.comDirect company coverage
Pierre & Vacances-Center Parcs: Total Number of Shares and Voting Rights
Pursuant to Article L. 233-8 of the French Commercial Code and Article 223-16 of the General Regulations of the French Autorité des marchés financiers PARIS, August 12, 2026--(BUSINESS WIRE)--Regulatory News: Pierre & Vacances-Center Parcs (Paris:VAC): Date Number of shares(*) Number of theoretical voting rights Number of actual voting rights (exercisable at General Meetings) (**) 31 July 2026 462 008 714 462 008 714 461 904 805 (*) Ordinary shares only, i.e. excluding 1,130 preferred shares not admitted to trading. (**) Excluding treasury shares, which are deprived of voting rights (the 1,130
Regulation
- Published
- 12 Aug 2026 13:37
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#373Tone
finance.yahoo.comDirect company coverage
technotrans SE (WBO:TTR1) (Q2 2026) Earnings Call Highlights: Margin Resilience and Strategic ...
This article first appeared on GuruFocus. Revenue: EUR113.3 million in H1 2026, down 6% from EUR120.6 million in the prior year. EBIT: EUR8.0 million in H1 2026, compared to EUR8.4 million one year ago. EBIT Margin: Increased to 7.1% from 7.0% in the prior year. Gross Profit: EUR34.2 million, with gross margin improving to 30.2% from 29.8%. EBITDA: EUR11.2 million, compared to EUR11.9 million in the previous year; EBITDA margin rose to 9.9% from 9.8%. Net Profit: EUR4.9 million, down from EUR5.2 million in the prior year. Earnings Per Share: EUR0.71, compared to EUR0.75 in the previous year. F
EarningsGrowth RateGuidancePlasticsRevenueSupply Chain
- Published
- 12 Aug 2026 01:02
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#482Tone
finance.yahoo.comDirect company coverage
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investmen
BiotechCompetitionEarningsFda ApprovalOncologyQuarterly Results
- Published
- 11 Aug 2026 14:30
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#578Tone
finance.yahoo.comDirect company coverage
Rational AG (RATIY) (Q2 2026) Earnings Call Highlights: Record EBIT Margin and Strategic ...
This article first appeared on GuruFocus. Revenue (H1 2026): EUR642 million, up 8% organically and 6% after FX adjustments. Revenue (Q2 2026): EUR324 million, up 4% year-over-year. EBIT (H1 2026): EUR170 million, up 11% year-over-year, with a margin of 26.5% (24.3% excluding tariff refunds). Gross Margin (H1 2026): Improved to 59.8%. Operating Expenses (H1 2026): Increased 5% year-over-year to EUR250 million. iCombi Revenue (H1 2026): EUR562 million, up 5%. iVario Revenue (H1 2026): EUR79 million, up 14%, with North America growing 24%. Germany Revenue (H1 2026): Up 9%. Europe (ex-Germany) Rev
EarningsEBIT MarginGrowth RateGuidanceRevenue GrowthRevenue Growth
- Published
- 11 Aug 2026 01:04
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#648Tone
finance.yahoo.comDirect company coverage
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due to higher SG&A expenses tied to costs associated with the commercial launch of Myqorzo and lower revenues. Revenues amounted to $28.6 million, which went down from $66.8 million in the year-ago quarter but surpassed the Zacks Consensus Estimate of $20 million. Cytokinetics' shares have surged 28.1% year to date compared with the ind
BiotechClinical TrialsEarningsFda ApprovalFourth QuarterPharma
- Published
- 07 Aug 2026 18:22
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#784Tone
finance.yahoo.comDirect company coverage
Bittium Oyj (HLSE:BITTI) Earnings Reset The Valuation Debate
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. How Bittium Oyj's Latest Earnings Shape the Investment Picture Bittium Oyj (HLSE:BITTI) reported half year 2026 sales of €57.9 million and net income of €7.5 million, compared with €42.3 million and €1.5 million a year earlier, which sharpened investor focus on the stock. Those figures, together with basic earnings per share from continuing operations of €0.211 compared with €0.043 a year ago, provide fresh data to reassess
Balance SheetDefenseEarningsEarnings GrowthEarnings Per ShareNet Income
- Published
- 07 Aug 2026 18:10
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.